TS
MDGL icon

Thomas Steyer’s Madrigal Pharmaceuticals MDGL Stock Holding History

Thomas Steyer’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,319
Closed -$1.74M – 145
2026
Q1 		$1.74M Hold
3,319
– – 0.01% 98
2025
Q4 		$1.93M Hold
3,319
– – 0.01% 80
2025
Q3 		$1.52M Hold
3,319
– – 0.01% 84
2025
Q2 		$1M Hold
3,319
– – ﹤0.01% 91
2025
Q1 		$1.1M Hold
3,319
– – 0.01% 93
2024
Q4 		$1.02M Hold
3,319
– – ﹤0.01% 98
2024
Q3 		$704K Hold
3,319
– – ﹤0.01% 108
2024
Q2 		$930K Hold
3,319
– – ﹤0.01% 109
2024
Q1 		$886K Hold
3,319
– – ﹤0.01% 122
2023
Q4 		$768K Hold
3,319
– – ﹤0.01% 109
2023
Q3 		$485K Hold
3,319
– – ﹤0.01% 118
2023
Q2 		$767K Sell
3,319
-160,500
-98% -$43.5M ﹤0.01% 126
2023
Q1 		$39.7M Buy
163,819
+10,819
+7% +$2.95M 0.22% 65
2022
Q4 		$44.4M Buy
+153,000
New +$15M 0.26% 65

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Thomas Steyer's MDGL Position: Q2 2026 in Review

Thomas Steyer sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2026, closing a stake of 3,319 shares — an estimated $1.74M sold.

Thomas Steyer first reported a position in MDGL in Q4 2022 and held it in 14 quarters. The position peaked at $44.4M in Q4 2022. 411 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Thomas Steyer reported no remaining Madrigal Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Thomas Steyer sold 3,319 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $1.74M.
  • Thomas Steyer first reported a position in Madrigal Pharmaceuticals in Q4 2022 and held it in 14 quarters.
  • Thomas Steyer's Madrigal Pharmaceuticals position peaked at $44.4M in Q4 2022.
  • 411 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.